化合物 RUNX1/ETO tetramerization-IN-1,RUNX1/ETO tetramerization-IN-1

化合物 RUNX1/ETO tetramerization-IN-1|T61098|TargetMol

价格 2350 10600 13800
包装 2mg 25mg 50mg
最小起订量 2mg
发货地 上海
更新日期 2026-05-08
QQ交谈 微信洽谈

产品详情

中文名称:化合物 RUNX1/ETO tetramerization-IN-1英文名称:RUNX1/ETO tetramerization-IN-1
CAS:88755-39-9品牌: TargetMol
产地: 美国保存条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature.
产品类别: 抑制剂
货号: T61098
2026-05-08 化合物 RUNX1/ETO tetramerization-IN-1 RUNX1/ETO tetramerization-IN-1 2mg/2350RMB;25mg/10600RMB;50mg/13800RMB 2350 TargetMol 美国 Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. 抑制剂

Product Introduction

Bioactivity

名称RUNX1/ETO tetramerization-IN-1
描述RUNX1/ETO tetramerization-IN-1 is a small-molecule inhibitor that specifically targets NHR2 of RUNX1/ETO, effectively inhibiting the tetramerization process. With an EC50 value of 0.25 μM, this compound successfully restores gene expression that has been down-regulated by RUNX1/ETO. Furthermore, RUNX1/ETO tetramerization-IN-1 demonstrates promising anti-leukemic activity by inhibiting the proliferation of SKNO-1 cells dependent on RUNX1/ETO and significantly reducing RUNX1/ETO-associated tumor growth in a mouse model [1] [2] [3].
体外活性RUNX1/ETO is composed by the DNA-binding Runt-domain5, the product of the RUNX1 gene, and by four nervy homology regions (NHR1-4), the product of the ETO gene. The NHR2 domain is responsible for the tetramerization of RUNX1/ETO. RUNX1/ETO tetramerization-IN-1 (compound 7.44) (1 μM and 10 μM; 3, 5, 7 d) selectively reduces the viability of RUNX1/ETO-dependent human leukemic SKNO-1 cells instead of U937 cells [1]. RUNX1/ETO tetramerization-IN-1 (compound 7.44) (25 μM and 50 μM; 5 d) inhibits the growth of and induces myeloid differentiation in RUNX1/ETO-expressing cells (SKNO-1, Kasumi-1, and K562) [2]. RUNX1/ETO tetramerization-IN-1 (100 μM; 7 d) induces growth-arrest and differentiation of RUNX1/ETOtr-expressing CD34 + progenitor cells [2]. RUNX1/ETO tetramerization-IN-1 (compound 7.44) has favorable physicochemical and ADME properties with high aqueous solubility, high stability in buffer and plasma, and a low hepatic intrinsic clearance in vitro, with the aqueous solubility of 60 μg/mL [3]. RUNX1/ETO tetramerization-IN-1 (1 μM and 10 μM) shows a potential to inhibit CYP2B6, 2C9, 2C19, and 3A4 [3]. RUNX1/ETO tetramerization-IN-1 (compound 8) (50 μM; 16 h) inhibits c-Jun N-terminal kinase (JNK) and affect the JNK-pathway in cells [4]. Cell Viability Assay [1] Cell Line: RUNX1/ETO-dependent human leukemic SKNO-1 and U937 cells Concentration: 1 μM and 10 μM Incubation Time: 3, 5, 7 days Result: Inhibited the SKNO-1 cell growth specifically. Cell Viability Assay [3] Cell Line: Pharmacokinetic properties of RUNX1/ETO tetramerization-IN-1 Concentration: Incubation Time: Result: Kinetic solubility (99% PBS, 1% DMSO) 177 μM Plasma protein binding (mouse plasma, 60 min) 98.4% Plasma stability (mouse plasma, 0–240 min) No degradation Hepatocyte stability (mouse hepatocytes) 2.5 μL/min/million cells Chemical stability in PBS (0–4 h) No degradation
体内活性RUNX1/ETO tetramerization-IN-1 (compound 7.44) (200-250 μg/kg; i.p.; 5 times per week; 130 d) delays tumor growth of RUNX1/ETO cells in mice [2]. Animal Model: NSG immunodeficient mice (NOD.Cg-Prkdc scid Il2rg tm1WjI /SzJ) injected with Kasumi-1 cells [2] Dosage: 200-250 μg/Kg Administration: Intraperitoneal injection; 5 times per week, for 130 days Result: Reduced the dissemination of leukemic cells, remained 75% mice alive at day 130 post-treatment.
存储条件Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature.
br
关键字: RUNX1/ETO tetramerization-IN-1|TargetMol

公司简介

TargetMol Chemicals Inc. 总部位于马萨诸塞州波士顿,致力于为全球生化领域科学家的研究提供专业的产品和服务。TargetMol?品牌的客户群分布于40多个国家和地区,已发展成为全球知名的化合物库和小分子化合物研究供应商。 TargetMol?可提供160多种满足不同需求的化合物库,以及多种类型的生化试剂产品,包括12000多种抑制剂、16000多种天然产物和各类多肽、抗体、生命科学试剂盒等,此外,我们还建设有CADD(计算机辅助药物设计)研究中心、药理实验室、药化合成平台三大技术中心,全方位满足客户的定制需求。 凭借我们优质的产品和服务、快速高效的全球供应链和专业的技术支持,我们将有效帮助您缩短研发周期,取得更成功的结果。
成立日期 2013-04-18 (14年) 注册资本 589.8595万人民币
员工人数 100-500人 年营业额 ¥ 1亿以上
主营行业 中间体,天然产物,生物化工,化学试剂,生物技术服务 经营模式 贸易,工厂,试剂,定制,服务
  • TargetMol中国(陶术生物)
VIP 3年
  • 公司成立:14年
  • 注册资本:589.8595万人民币
  • 企业类型:有限责任公司(自然人投资或控股)
  • 主营产品:抑制剂&激动剂,天然产物,重组蛋白,化合物库,技术服务
  • 公司地址:上海市静安区江场三路238号8楼
询盘

化合物 RUNX1/ETO tetramerization-IN-1|T61098|TargetMol相关厂家报价

产品名称 价格   公司名称 报价日期
询价
VIP1年
河南伊诺凯新材料有限公司
2026-06-10
询价
VIP5年
湖北魏氏化学试剂股份有限公司
2026-06-11
¥9999
苏州靖驰医药科技有限公司
2026-04-15
内容声明:
以上所展示的信息由商家自行提供,内容的真实性、准确性和合法性由发布商家负责。 商家发布价格指该商品的参考价格,并非原价,该价格可能随着市场变化,或是由于您购买数量不同或所选规格不同而发生变化。最终成交价格,请咨询商家,以实际成交价格为准。请意识到互联网交易中的风险是客观存在的
主页 | 企业会员服务 | 广告业务 | 联系我们 | 旧版入口 | 中文MSDS | CAS Index | 常用化学品CAS列表 | 化工产品目录 | 新产品列表 |投诉中心
Copyright © 2008 ChemicalBook 京ICP备07040585号  京公海网安备110108000080号  All rights reserved.